Readmission Following Prostatic Surgery

NCT ID: NCT06101576

Last Updated: 2023-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

4000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-01

Study Completion Date

2025-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be conducted to estimate readmission rate and reasons for readmission after all modalities of endoscopic transurethral surgeries for treatment of BOO secondary to BPH in the last 20 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Computerized patient information system (PIS) of Urology and Nephrology Center (UNC) and database of prostate unit of UNC will be reviewed for all preoperative, intraoperative and post discharge data. All follow up visits will be traced for outcome measurement. Patients with no hospital follow up visit will be contacted by phone and interrogated about their LUTS control state, ongoing medication and history of secondary procedures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

BPH With Urinary Obstruction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transurethral incision of the prostate (TUIP)

Patients who underwent TUIP using electrocautery or Laser.

TUIP

Intervention Type PROCEDURE

Patient who underwent transurethral incision of the prostate (TUIP) using electrical current or laser beam.

Transurethral resection of the prostate (TURP)

Patients who underwent TURP using monopolar or bipolar electrocautery.

TURP

Intervention Type PROCEDURE

Patient who underwent transurethral resection of the prostate (TURP) using momopolar or bipolar current.

Prostate Vaporization

Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).

Prostate Vaporization

Intervention Type PROCEDURE

Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).

Anatomical endoscopic enucleation of the prostate (AEEP)

Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.

AEEP

Intervention Type PROCEDURE

Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TUIP

Patient who underwent transurethral incision of the prostate (TUIP) using electrical current or laser beam.

Intervention Type PROCEDURE

TURP

Patient who underwent transurethral resection of the prostate (TURP) using momopolar or bipolar current.

Intervention Type PROCEDURE

Prostate Vaporization

Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).

Intervention Type PROCEDURE

AEEP

Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Men who underwent transurethral prostatic surgery for BPH causing BOO at Urology and Nephrology Center, Mansoura University, Egypt from Jun. 2005 to Dec. 2024.

Exclusion Criteria

1. Patients who underwent TUR tunnelling for prostatic adenocarcinoma.
2. LUTS secondary to neuropathic bladder.
3. Incidentally diagnosed prostate cancer after surgery
Minimum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mansoura University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed R EL-Nahas, MD

Role: PRINCIPAL_INVESTIGATOR

Urology and Nephrology Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Urology and Nephrology Center

Al Mansurah, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ahmed R EL-Nahas, MD

Role: CONTACT

+201221136899

Amr W Yehia, MD

Role: CONTACT

+201027383536

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ahmed R EL-Nahas, MD

Role: primary

00201221136899

Amr W Yehia, MD

Role: backup

+201027383536

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2436

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HoLEP Vs BPEP for Large Prostatic Adenoma
NCT04275076 COMPLETED PHASE3